SABCS 2024 | Advances in breast cancer genetics: risk assessment & resistance mechanisms

Claudine Isaacs • 16 Dec 2024

SABCS 2024

Breast Cancer

Claudine Isaacs, MD, Georgetown University, Washington, DC, discusses key advancements in cancer genetics, including strategies to address variants of uncertain significance (VUS). Novel risk assessment models integrating genetic and standard risk factors for more accurate predictions across diverse populations are discussed. Dr Isaacs additionally highlights how reversion mutations are associated with resistance to BRCA1/2 inhibitors, emphasizing the need to refine therapies and improve clinical outcomes for affected patients. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.